1 Read those four numbers together, because the contrast is the useful part
The trial protocol did not specify a particular time of day for injections, which is itself an informative data point
& Eijsvogels, T
Clinical studies on pharmacological therapies for MC4R -deficient obesity Before reviewing individual pharmacological agents, it is essential to acknowledge the inherent limitations of the evidence supporting their use, specifically in MC4R -deficient obesity
You may be unsuitable for this slimming injection if you: Have any known allergies to ingredients in it Are breastfeeding, pregnant or planning to conceive Are over 75 years old or under 18 years Have severe heart failure Have diabetes and currently take other medications containing GLP-1 (lixisenatide or exenatide) or have hypoglycaemia (low blood sugar) Have severe gut or stomach problems like inflammatory bowel disease or gastroparesis (delayed stomach emptying) Have severe kidney or liver disease or on dialysis Ensure you mention to your weight loss doctor the following conditions: Pancreatic diseases Diabetes Gallstones or inflamed gallbladder A racing heart or heart palpitations Thyroid diseases, including enlargement of the thyroid gland and thyroid nodules Mild to moderate kidney or liver disease A condition requiring you to take anticoagulants such as warfarin Inflamed gallstones or gallbladder Included in our protocol, is screening for the above, so when you access our service, we will assess you to ensure safety of these medications
Evidence supports use in rapid weight loss to reduce gallstone formation (bariatric context
